Kodiak Sciences reports Phase 3 wins for Zenkuda and tabirafusp-ted, outlines BLA timelinesNov 12Quarterly update4D Molecular TherapeuticsKodiak Sciences Inc
AbbVie posts updates on three early-stage trials: obesity, drug interaction, glabellar linesNov 6Weekly roundup, 5 itemsABBV-295AbbVieUpdated
Regeneron-linked TOP2201 posts results; NeoSTOP-IT terminated, DEUTERON completedNov 5Weekly roundup, 7 itemsafliberceptALN-CIDEBUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's programOct 29Quarterly updateAlnylam Pharmaceuticalsnucresiran
Regeneron: AcTED results posted; new REGN9220 and glaucoma trials registeredOct 23Weekly roundup, 4 itemsafliberceptcemiplimab-rwlcUpdated
FDA clears second submission under Sandoz's Enzeevu biologics license applicationOct 22Regulatory decisionaflibercept-abzvSandoz
FDA records second original approval for Amgen's PavbluOct 22Regulatory decisionaflibercept-ayyhAmgen
FDA approves new dosage form application for Formycon's biosimilar AhzantiveOct 22Regulatory decisionaflibercept-mrbb
Boehringer Ingelheim posts Brightline-2 brigimadlin results; BI 4060107 trial recruitsOct 15Weekly roundup, 5 itemsBoehringer Ingelheimempagliflozin
Bayer posts Phase 3 gadoquatrane brain/spine MRI results; ARI2 Eylea data remain on fileOct 8Weekly roundup, 2 itemsafliberceptBayerUpdated
Kodiak's Zenkuda and tabirafusp-ted hit primary endpoints in Phase 3 DAYBREAK trialSep 28Clinical readout4D Molecular TherapeuticsKodiak Sciences Inc
Ollin Biosciences registers two Phase 3 trials of OLN324 for diabetic macular edemaSep 25Weekly roundup, 2 itemsOllin Biosciences, Inc
Regeneron's EYLEA HD posts Phase 3b safety results; dupilumab keloid study completesSep 18Weekly roundup, 2 itemsafliberceptdupilumab
4DMT reports Q2 2026 results, completes enrollment for second wet AMD Phase 3 trialAug 13Quarterly update4D Molecular Therapeutics
Kodiak reports Q2 2026 results, confirms three Phase 3 readouts by year-endAug 13Quarterly updateKodiak Sciences Inc
Ocular Therapeutix targets Q4 2026 AXPAXLI NDA filing for wet AMD after FDA meetingAug 3Quarterly updateOcular Therapeutix, Inc.
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab
Kodiak Sciences recruiting Phase 3 ALTO trial testing tabirafusp tedromer vs. aflibercept in DMEJul 29Trial updateafliberceptKodiak Sciences Inc
Merck completes MK-4082 obesity pill PK study; adds V132 vaccine and belzutifan pediatric trialsJul 17Weekly roundup, 8 itemsbelzutifanDaiichi Sankyo